[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

August 2017 - April 2015

Decade

Year

Issue

January 2016, Vol 2, No. 1, Pages 3-152

Viewpoint

A Call for Value in Cancer Research

Abstract Full Text
JAMA Oncol. 2016;2(1):11-12. doi:10.1001/jamaoncol.2015.3706

This Viewpoint suggests ways to add efficiency to cancer research, including decreased costs as an explicit goal of clinical trials, data sharing, and enhanced accountability for cancer research dollars.

Next-Generation Sequencing in Oncology in the Era of Precision Medicine

Abstract Full Text
JAMA Oncol. 2016;2(1):13-14. doi:10.1001/jamaoncol.2015.4503

This Viewpoint highlights the role of next-generation sequencing in the rapid emergence of new cancer therapies as well as the challenges of safely regulating these therapies without unnecessarily delaying their implementation.

PD-L1 Testing in CancerChallenges in Companion Diagnostic Development

Abstract Full Text
JAMA Oncol. 2016;2(1):15-16. doi:10.1001/jamaoncol.2015.4685

This Viewpoint summarizes the role of PD-1 and PD-L1 in antibody therapies to treat certain cancers and calls for a harmonization in developing PD-1/PD-L1 inhibitors and assays to standardize testing to further this cancer therapy.

Health, Wealth, and the 21st Century Cures Act

Abstract Full Text
JAMA Oncol. 2016;2(1):17-18. doi:10.1001/jamaoncol.2015.4221

This Viewpoint describes why the 21st Century Cures Act will be a milestone in US legislation, for drug development, medical innovation and research, and benefits to patients.

Editorial

Perspectives on Cost and Value in Cancer Care

Abstract Full Text
JAMA Oncol. 2016;2(1):19-21. doi:10.1001/jamaoncol.2015.4191

Trastuzumab and Cardiac Outcomes in Breast CancerA Story We Know by Heart?

Abstract Full Text
JAMA Oncol. 2016;2(1):21-22. doi:10.1001/jamaoncol.2015.3866

Cancer Hallmark–Based Gene Sets and Personalized Medicine for Patients With Stage II Colon Cancer

Abstract Full Text
JAMA Oncol. 2016;2(1):23-24. doi:10.1001/jamaoncol.2015.3614

Enlisting the Immune System to Cure Breast Cancer—A Recipe for Success

Abstract Full Text
JAMA Oncol. 2016;2(1):25-27. doi:10.1001/jamaoncol.2015.3236
Original Investigation

Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer

Abstract Full Text
JAMA Oncol. 2016;2(1):29-36. doi:10.1001/jamaoncol.2015.3709

This phase II cohort study examined the cardiac safety of paclitaxel and trastuzumab in patients with node-negative, ERBB2-positive breast cancer and found that the cardiac toxic effects were low, suggesting that left ventricular ejection fraction monitoring could be simplified for many patients.

Identification and Construction of Combinatory Cancer Hallmark–Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer

Abstract Full Text
JAMA Oncol. 2016;2(1):37-45. doi:10.1001/jamaoncol.2015.3413

This genetic database analysis of stage II colon cancer samples finds that certain gene signature sets may serve as prognostic predictors and facilitate the identification of patients who could gain survival benefit from fluorouracil adjuvant chemotherapy.

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

Abstract Full Text
JAMA Oncol. 2016;2(1):46-54. doi:10.1001/jamaoncol.2015.3638

This study uses rabbit monoclonal antibodies to demonstrate PD-L1 protein expression in human non–small-cell lung cancer biopsy specimens and found heterogeneity within tumors and interassay discordance.

Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer

Abstract Full Text
JAMA Oncol. 2016;2(1):56-64. doi:10.1001/jamaoncol.2015.3239

This exploratory analysis of data from the N9831 trial evaluated the association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in women with human epidermal growth factor receptor 2 (HER2)–positive breast cancer treated with chemotherapy or chemotherapy plus trastuzumab.

Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast CancerA Systematic Review and Meta-analysis

Abstract Full Text
has active quiz
JAMA Oncol. 2016;2(1):65-73. doi:10.1001/jamaoncol.2015.3251

This systematic review and meta-analysis provides evidence suggesting that gonadotropin-releasing hormone agonists given concurrently with chemotherapy to premenopausal patients undergoing treatment for early-stage breast cancer is associated with prevention of early menopause.

Time-Limited Trials of Intensive Care for Critically Ill Patients With CancerHow Long Is Long Enough?

Abstract Full Text
JAMA Oncol. 2016;2(1):76-83. doi:10.1001/jamaoncol.2015.3336

This decision analysis study investigated the optimal duration of time-limited trials of intensive care among critically ill patients with cancer.

Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer

Abstract Full Text
JAMA Oncol. 2016;2(1):85-93. doi:10.1001/jamaoncol.2015.3384

This study of a SEER-Medicare linked database found that black men treated with radical prostatectomy for prostate cancer are more likely to experience adverse events and incur higher costs compared with non-Hispanic white men, but this does not translate into a difference in mortality.

Temporal Trends in Postmastectomy Radiation Therapy and Breast Reconstruction Associated With Changes in National Comprehensive Cancer Network Guidelines

Abstract Full Text
JAMA Oncol. 2016;2(1):95-101. doi:10.1001/jamaoncol.2015.3717

This study of SEER data on women with stage I to III breast cancer undergoing mastectomy investigated whether changes in National Comprehensive Cancer Network guidelines have increased use of postmastectomy radiation therapy and affected receipt of breast reconstruction.

Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA

Abstract Full Text
JAMA Oncol. 2016;2(1):104-111. doi:10.1001/jamaoncol.2015.5208

This large case series found that germline variants were common in individuals with advanced cancer who underwent tumor-normal genetic sequencing, which may prove useful in revealing otherwise unsuspected syndromic associations.

Comparison of Adverse Events for Endoscopic vs Percutaneous Biliary Drainage in the Treatment of Malignant Biliary Tract Obstruction in an Inpatient National Cohort

Abstract Full Text
JAMA Oncol. 2016;2(1):112-117. doi:10.1001/jamaoncol.2015.3670

This cohort study uses National Inpatient Sample database data to compare the incidence of procedure-related adverse events with endoscopic vs percutaneous drainage of malignant biliary tract obstruction..

Brief Report

Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based ChemotherapyA Report From the US Food and Drug Administration

Abstract Full Text
JAMA Oncol. 2016;2(1):118-122. doi:10.1001/jamaoncol.2015.3934

This report details benefit-risk assessment and rationale for expedited approval by the US Food and Drug Administration of nivolumab, a new therapy for metastatic squamous non–small-cell lung cancer.

Invited Commentary

PD-L1 Expression as a Predictive BiomarkerIs Absence of Proof the Same as Proof of Absence?

Abstract Full Text
JAMA Oncol. 2016;2(1):54-55. doi:10.1001/jamaoncol.2015.3782

Failure of Ovarian Suppression With Gonadotropin-Releasing Hormone Analogs to Preserve FertilityAn Assessment Based on the Quality of Evidence

Abstract Full Text
JAMA Oncol. 2016;2(1):74-75. doi:10.1001/jamaoncol.2015.3252

Critically Ill Patients’ Preferences Regarding Aggressive Medical InterventionsCan We Hear the Patient’s Voice?

Abstract Full Text
JAMA Oncol. 2016;2(1):83-84. doi:10.1001/jamaoncol.2015.3613

The Meaning of Race in Prostate Cancer Treatment

Abstract Full Text
JAMA Oncol. 2016;2(1):93-94. doi:10.1001/jamaoncol.2015.3615

Postmastectomy Radiation Therapy and Breast Reconstruction—Marching Forward Together or Apart?

Abstract Full Text
JAMA Oncol. 2016;2(1):102-103. doi:10.1001/jamaoncol.2015.3826
Review

Current Therapy and New Directions in the Treatment of Hairy Cell LeukemiaA Review

Abstract Full Text
JAMA Oncol. 2016;2(1):123-129. doi:10.1001/jamaoncol.2015.4134

This review summarizes current management of hairy cell leukemia and novel therapies currently under investigation in clinical trials or already in use.

From The JAMA Network

Outcomes of Patients With Multiple Cutaneous Squamous Cell Carcinomas

Abstract Full Text
JAMA Oncol. 2016;2(1):130-131. doi:10.1001/jamaoncol.2015.3894

This commentary reviews the conclusions of a study concerning number of cutaneous squamous cell carcinomas (CSCCs) and patient outcomes and reiterates the importance of examinations for patients with multiple CSCCs.

JAMA Oncology Diagnostic Test Interpretation

Next-Generation Sequencing for the Identification of Targetable Molecular Alterations in Cancer

Abstract Full Text
JAMA Oncol. 2016;2(1):132-133. doi:10.1001/jamaoncol.2015.3788

This diagnostic challenge describes a patient who presented with progressive inguinal lymphadenopathy and a leukocytosis of 144 000/µL with 97% lymphocytes who eventually achieved complete remission but experienced disease recurrence 6 months later.

Research Letter

Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells

Abstract Full Text
JAMA Oncol. 2016;2(1):134-136. doi:10.1001/jamaoncol.2015.3940

Academic scientists and scientists employed by manufacturers of erythropoiesis-stimulating agents report opposite findings in studies of the existence of functional erythropoietin receptors on cancer cells.

Use of Preoperative PET/CT Staging in Sentinel Lymph Node–Positive Melanoma

Abstract Full Text
JAMA Oncol. 2016;2(1):136-137. doi:10.1001/jamaoncol.2015.3664

This retrospective review finds that positron emission tomography coupled with computed tomography has a high false-positive rate for sentinel lymph node mapping.

Patient Income Level and Cancer Clinical Trial ParticipationA Prospective Survey Study

Abstract Full Text
JAMA Oncol. 2016;2(1):137-139. doi:10.1001/jamaoncol.2015.3924

This survey finds that lower patient income level is associated with lower likelihood of clinical trial participation.

The Use of Superlatives in Cancer Research

Abstract Full Text
JAMA Oncol. 2016;2(1):139-141. doi:10.1001/jamaoncol.2015.3931

This investigation of recent news coverage of cancer research found that although most new cancer drugs offer only modest benefits, they are often described in the news media with superlatives, such as “revolutionary” and “game changer,” that may be unwarranted.

Comment & Response

Neoepitopes and CD3-Positive and CD8-Positive Cells in Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers

Abstract Full Text
JAMA Oncol. 2016;2(1):141. doi:10.1001/jamaoncol.2015.3900

Neoepitopes and CD3-Positive and CD8-Positive Cells in Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers—Reply

Abstract Full Text
JAMA Oncol. 2016;2(1):141-142. doi:10.1001/jamaoncol.2015.3903

Evaluating Chemotherapy at the End of Life

Abstract Full Text
JAMA Oncol. 2016;2(1):142. doi:10.1001/jamaoncol.2015.4102

Evaluating Chemotherapy at the End of Life

Abstract Full Text
JAMA Oncol. 2016;2(1):142-143. doi:10.1001/jamaoncol.2015.4105

Evaluating Chemotherapy at the End of Life

Abstract Full Text
JAMA Oncol. 2016;2(1):143-144. doi:10.1001/jamaoncol.2015.4108

Evaluating Chemotherapy at the End of Life—Reply

Abstract Full Text
JAMA Oncol. 2016;2(1):144. doi:10.1001/jamaoncol.2015.4111

Factors in Association Between Parkinson Disease and Risk of Cancer in Taiwan

Abstract Full Text
JAMA Oncol. 2016;2(1):144-145. doi:10.1001/jamaoncol.2015.4151

Factors in Association Between Parkinson Disease and Risk of Cancer in Taiwan—Reply

Abstract Full Text
JAMA Oncol. 2016;2(1):145-146. doi:10.1001/jamaoncol.2015.4148
Editor's Note

Balancing Benefit, Risk, and Time to New Cancer Therapies

Abstract Full Text
free access
JAMA Oncol. 2016;2(1):122. doi:10.1001/jamaoncol.2015.4126
Correction

Error in Byline

Abstract Full Text
free access
JAMA Oncol. 2016;2(1):146. doi:10.1001/jamaoncol.2015.5748

Error in Figure Presentation

Abstract Full Text
free access
JAMA Oncol. 2016;2(1):146. doi:10.1001/jamaoncol.2015.5816

Error in Abstract Results

Abstract Full Text
free access
JAMA Oncol. 2016;2(1):146. doi:10.1001/jamaoncol.2015.6255
JAMA Oncology Patient Page

Portacaths

Abstract Full Text
free access
JAMA Oncol. 2016;2(1):152. doi:10.1001/jamaoncol.2015.3488
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2016;2(1):5. doi:10.1001/jamaoncol.2015.3478
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2016;2(1):3. doi:10.1001/jamaoncol.2015.3477
×